Copyright © 2021. Inderes Oyj. All rights reserved.

Redeye returns with a follow-up note to Genovis’ Q1’22 report. We are encouraged to see that the company is reporting yet another solid quarter and that the growth remains high, particularly in the Enzyme business. We continue to see Genovis as an attractive investment for the long-term investor and reiterate our Base Case.

Lähde: Finwire News

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.